Phase II Study of Rituximab in Patients With Immune Thrombocytopenic Purpura
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
OBJECTIVES: I. Determine the response rate and response duration to rituximab in patients
with immune thrombocytopenic purpura.
II. Evaluate the toxicity associated with this treatment regimen in these patients.
III. Evaluate the alteration in antiplatelet antibody with this treatment regimen in these
patients.